Semnur Pharmaceuticals, Inc. (SMNR) Stock Price & Analysis
Semnur Pharmaceuticals, Inc. (SMNR) fell 38.00% to USD 3.1 as of June 10, 2026 at 12:18 UTC, according to Nexqual real-time market data.
SMNR last closed at USD 5; the session ranged USD 3.1–3.1 on volume of 100 shares. Market capitalization is $713.65M, with a 52-week range of USD 3–23 (PNK). Source: Nexqual, June 10, 2026 at 12:18 UTC.
Key Statistics (as of June 10, 2026 at 12:18 UTC)
| Price | USD 3.1 |
|---|---|
| Change | ▼ 38.00% (down) |
| Previous Close | USD 5 |
| Open | USD 3.1 |
| Day Range | USD 3.1 – 3.1 |
| 52-Week Range | USD 3 – 23 |
| Volume | 100 shares |
| Market Cap | $713.65M |
| Exchange | PNK |
Technical Analysis (SMNR)
Nexqual's technical model rates SMNR "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 12:18 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 34.15 (neutral) |
| vs SMA50 | Below (USD 6.23) |
| MACD | -0.57 (negative) |
Analyst Ratings (SMNR)
Wall Street analysts rate SMNR "None", per Nexqual as of June 10, 2026 at 12:18 UTC.
| Consensus Rating | None |
|---|
Earnings (SMNR)
Source: Nexqual, June 10, 2026 at 12:18 UTC.
Financials & Fundamentals (SMNR)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.12 |
| Total Cash | $103,000 |
| Total Debt | $19.68M |
| Free Cash Flow | $52.84M |
Source: Nexqual, June 10, 2026 at 12:18 UTC.
Financial Health Score (SMNR)
Nexqual rates Semnur Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 12:18 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $103K cash vs $20M debt |
| Cash Flow | Weak — Operating cash flow -$8M |
| Efficiency | Mixed — No data |
Ownership (SMNR)
| Insider Ownership | +87.34% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 230.21M |
| Float | 29.71M |
Source: Nexqual, June 10, 2026 at 12:18 UTC.
Leadership (SMNR)
Semnur Pharmaceuticals, Inc. is led by Henry H. Ji (age 61), CEO, President & Executive Chairperson, per Nexqual as of June 10, 2026 at 12:18 UTC.
| CEO, President & Executive Chairperson | Henry H. Ji (age 61) |
|---|---|
| COO, Senior VP, CFO & Secretary | Stephen Ma (age 52) |
From Semnur Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Semnur Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain.
- Its lead product candidate is SP-102, a novel viscous gel formulation of corticosteroid to treat lumbosacral radicular pain, or sciatica, which is in the second Phase 3 study.
- Semnur Pharmaceuticals, Inc. operates as a subsidiary of Scilex Holding Company.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SCLX | Scilex Holding Company | USD 7.04 | ▲ 0.57% |
| ALM | Almonty Industries Inc. | USD 15.97 | ▼ 2.08% |
| SCLXW | Scilex Holding Company | USD 0.14 | ▼ 0.07% |
| AUPH | Aurinia Pharmaceuticals Inc | USD 15.78 | ▼ 0.38% |
| AARD | Aardvark Therapeutics, Inc. | USD 3.58 | ▼ 2.72% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 12:18 UTC. This page is informational and not investment advice.